Skip to main content
. 2021 Mar 26;12:653989. doi: 10.3389/fimmu.2021.653989

Figure 4.

Figure 4

GSK126 inhibits ex vivo activation of IFN-I signaling pathway. (A) Experimental setting for the ex vivo tests. The mice were treated with a single dose of GSK126 (50 mg/kg, i.p.) and then sacrificed after 2 days. Splenocytes were isolated and stimulated with universal type I IFN (1,000 U/ml) for indicated time. (B, C) The levels of ISG15 mRNA (B) and IFIT3 mRNA (C) were measured. (A) Created with BioRender.com. (B, C) Data of three independent experiments are plotted and presented as mean ± SEM. P values were determined by two-way ANOVA.